Cryo-Cell International Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在医疗服务供应商行业排名57/78位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价8.50。中期看,股价处于下降通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
Cryo-Cell International Inc评分
相关信息
行业排名
57 / 78
全市场排名
285 / 4582
所属行业
医疗服务供应商
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
持有
评级
8.500
目标均价
+86.81%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Cryo-Cell International Inc亮点
亮点风险
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
公司代码CCEL
公司Cryo-Cell International Inc
CEOPortnoy (Mark L)
网址https://www.cryo-cell.com/
常见问题
Cryo-Cell International Inc(CCEL)的当前股价是多少?
Cryo-Cell International Inc(CCEL)的当前股价是 3.750。
Cryo-Cell International Inc的股票代码是什么?
Cryo-Cell International Inc的股票代码是CCEL。
Cryo-Cell International Inc股票的52周最高点是多少?
Cryo-Cell International Inc股票的52周最高点是8.790。
Cryo-Cell International Inc股票的52周最低点是多少?
Cryo-Cell International Inc股票的52周最低点是3.570。
Cryo-Cell International Inc的市值是多少?
Cryo-Cell International Inc的市值是30.21M。
Cryo-Cell International Inc的净利润是多少?
Cryo-Cell International Inc的净利润为402.10K。
现在Cryo-Cell International Inc(CCEL)的股票是买入、持有还是卖出?
根据分析师评级,Cryo-Cell International Inc(CCEL)的总体评级为持有,目标价格为8.500。
Cryo-Cell International Inc(CCEL)股票的每股收益(EPS TTM)是多少
Cryo-Cell International Inc(CCEL)股票的每股收益(EPS TTM)是-0.056。